-

Twist Bioscience Earns 2022 Great Place to Work Certification

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has earned Great Place to Work® Certification™ in the U.S. for the second consecutive year, and for the first time in China, Germany, Singapore, and the United Kingdom.

Great Place to Work is the global authority on workplace culture, employee experience and the leadership behaviors proven to deliver market-leading revenue, employee retention and increased innovation. Great Place to Work Certification recognizes employers who create an outstanding employee experience and is based on employee feedback and independent analysis.

“The results of the Great Place to Work survey showed that 85% of employees say that Twist is a great place to work and 90% are proud to tell others that they work at Twist,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “Our employees are our greatest asset and as Twist grows, we continue to intentionally take steps to strengthen our corporate culture and positive employee experience. This year we issued our first ESG report as a reflection of our commitment to building a diverse global workforce and inclusive work environment.”

“The average percentage of employees who say that their employer is a great workplace is 57% for a typical company in the U.S., making Twist well above average,” said Sarah Lewis-Kulin, vice president of global recognition at Great Place to Work. “Companies recognized with the Great Place to Work Certification show an ongoing commitment to employee experience.”

Twist offers employees development at all levels of the organization, diversity and cultural experiences, competitive compensation packages including comprehensive health and wellness benefits, equity in the company, robust family friendly policies including parental leave, paid time off to volunteer, and more. To learn more about working at Twist, please visit our Careers site. To learn more about Twist’s environmental, social and governance (ESG) efforts, please visit the ESG page of our website.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

Contacts

For Twist Bioscience:
Angela Bitting
SVP, Corporate Affairs
925- 202-6211
abitting@twistbioscience.com

Twist Bioscience Corporation

NASDAQ:TWST

Release Versions

Contacts

For Twist Bioscience:
Angela Bitting
SVP, Corporate Affairs
925- 202-6211
abitting@twistbioscience.com

More News From Twist Bioscience Corporation

Twist Bioscience Launches Next-Generation Library Preparation Kits Powered by Proprietary Enzymes

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched the Twist TrueAmp Library Preparation Kit and Twist PCR-Free WGS Library Preparation Kit, each designed to address a wide range of sample input, including low input and challenging sample types, to enable clinical research. The Twist TrueAmp Library Prep Kit brings a new level of exceptional performance to Twist’s library preparation portfolio, wi...

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 114,869 equity awards, consisting of 107,742 restricted stock units (“RSUs”) and up to 7,127 performance stock units (“PSUs”), will be granted to 52 recently hired individuals, in each case as an inducement material to their acceptance of employment wi...

Twist Bioscience Announces Fiscal 2026 First Quarter Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the first quarter fiscal 2026 ended December 31, 2025. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal first quarter 2026 earnings report and the investor presentation, or click https://investors.t...
Back to Newsroom